Ikarian Capital »

Dianthus Therapeutics shares owned by Ikarian Capital

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $14M 346k 39.35

More positions owned by Ikarian Capital

United Therapeutics Corporation Put Option (UTHR)
Spdr Series Trust S&p Biotech Put Option (XBI)
Genmab A/s Sponsored Ads (GMAB)
Bristol Myers Squibb Put Option (BMY)
Abivax Sa Sponsored Ads (ABVX)
Uniqure Nv Call Call Option
Insmed Com Par $.01 (INSM)
Ptc Therapeutics I (PTCT)
Ionis Pharmaceuticals (IONS)
Cidara Therapeutics Com New (CDTX)
Scholar Rock Hldg Corp Put Option (SRRK)
Rapt Therapeutics Com New (RAPT)
Maze Therapeatics (MAZE)
Soleno Therapeutics (SLNO)
Cytokinetics Com New (CYTK)

View all positions for Ikarian Capital

Top funds holding Dianthus Therapeutics

FMR
Fairmount Funds Management
Avidity Partners Management
RA Capital Management
Wellington Management Company
Octagon Capital Advisors
Point72 Asset Management
TCG Crossover Management
Vanguard Group
BlackRock
Bain Capital Life Sciences Investors
Vestal Point Capital
Citadel Advisors
VR Adviser
Alliancebernstein

View all funds holding Dianthus Therapeutics